Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EBITDA (2016 - 2026)

Ocular Therapeutix has reported EBITDA over the past 14 years, most recently at -$93.3 million for Q1 2026.

  • For Q1 2026, EBITDA fell 46.03% year-over-year to -$93.3 million; the TTM value through Mar 2026 reached -$299.4 million, down 46.73%, while the annual FY2025 figure was -$270.0 million, 57.19% down from the prior year.
  • EBITDA for Q1 2026 was -$93.3 million at Ocular Therapeutix, down from -$69.8 million in the prior quarter.
  • Over five years, EBITDA peaked at -$17.8 million in Q1 2022 and troughed at -$93.3 million in Q1 2026.
  • A 5-year average of -$41.0 million and a median of -$31.6 million in 2024 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: grew 11.84% in 2022 and later plummeted 152.25% in 2024.
  • Year by year, EBITDA stood at -$19.4 million in 2022, then decreased by 3.56% to -$20.0 million in 2023, then plummeted by 152.25% to -$50.6 million in 2024, then plummeted by 37.93% to -$69.8 million in 2025, then plummeted by 33.8% to -$93.3 million in 2026.
  • Business Quant data shows EBITDA for OCUL at -$93.3 million in Q1 2026, -$69.8 million in Q4 2025, and -$68.7 million in Q3 2025.